Table of Contents Table of Contents
Previous Page  377 / 812 Next Page
Information
Show Menu
Previous Page 377 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

S373

Objective

Zolpidem is a non-benzodiazepine hypnotic drug for

treatment of insomnia and is generally believed that is a safe medi-

cation. Therefore has been introduced as a lower potential agent for

dependency and abusive effects however its safety and dependence

potential are of great concern.

Case report

A 63 years old male patient had consulted a general

physician in January 2015 for his insomnia. He started on zolpi-

dem 10mg at bedtime. Over the next fewmonths he had gradually

increased the dose as he found the prescribed dose to be hav-

ing no significant effect. After abrupt discontinuation of zolpidem,

he presented to a center for drug users “AIDE ET ECOUTE” with

severe anxiety, impatience, loss of energy, insomnia, irritability,

headaches, and increased craving for higher dosage of zolpidem.

There was no history of any other substance abuse and he was diag-

nosed simultaneously a case of zolpidem dependence and major

depressive disorder.

Conclusions

Zolpidem has a potency to be abused with high

risk of dependency and withdrawal syndromes particularly among

elderly patients with comorbid anxiety and depressive disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1056

EV72

Nalmefene as an intermittent

treatment for alcohol abuse triggering

cocaine and sex consumption

A. Morera-Fumero

1 , 2 ,

, E. Diaz-Mesa

3

1

University of La Laguna, Internal Medicine – Dermatology and

Psychiatry, Santa Cruz de Tenerife, Spain

2

Psychiatric Consulting, Psychiatry, Santa Cruz de Tenerife, Spain

3

University Hospital of the Canary Islands, Psychiatry, La Laguna,

Spain

Corresponding author.

Nalmefene modulates the motivational system by blocking the

opioids receptors. Nalmefene indication is the alcohol consump-

tion reduction in alcoho dependent patients. We describe the case

of a patient with weekend alcohol abuse that was followed by

cocaine use and sex. After being treatedwith nalmefene, the patient

decreased alcohol consumption and did not engage cocaine use

and sex. The patient is a 36-year-old man with a previous his-

tory of cocaine, cannabis and alcohol abuse. After detoxification

the patient became aweekend drinker. Twomonths later he started

complaining that after drinking he needed to consume cocaine and

this led him to having sex with prostitutes. These behaviours had

a serious impact on his finances that lead him to asking for help.

Nalmefene, 18mg at dinner before going out, was prescribed. Tak-

ing one pill of nalmefene “allowedme to drink several shotswithout

feeling a need to continue drinking and, most importantly, I didn’t

feel the need to consume cocaine and have sex”. In an attempt to

ascertain if what had happened the previous weekend was “psy-

chological” the patient went out without taking nalmefene. The

pattern of alcohol use, control loss, and consumption of cocaine and

sex repeated itself. During the following two months, the patient

took nalmefene during dinner before going out every weekend and

the results were the same as when he first took the treatment.

Conclusion

Nalmefene may be helpful in the treatment of sev-

eral other addictions by blocking the positive reinforcements of

the drugs.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1057

EV73

A case of share psychotic disorder

induced by mephedrone

R.A. Baena

, Y. Lázaro , J. Rodriguez , L. Olivares , A. Matas ,

L. Niell

Hospital Clinico San Carlos, Psychyatry, Madrid, Spain

Corresponding author.

Introduction

Share psychotic disorder “folie à deux” is a rare con-

dition characterized by the transmission of delusional aspects from

a patient to another linked by a close relationship. We report the

case of two Spanish men who have experienced a combined delu-

sional episode induced by mephedrone.

Objectives

Describe a case of share psychotic disorder induced by

mephedrone. Make a review on scientific literature about the use

of mephedrone (little is known about the psychiatric consequences

of the use of these compounds). The patients had no psychiatric

history.

Aims

Show the danger of these novel drugs that are often bought

as apparently safe and legal.

Conclusions

Share psychotic disorder was first introduced by

Lasegue and Falret who hypothesized that transmission of psychi-

atric disturbance from one person to another was possible under

certain circumstances. The correlation of symptoms with the intake

of these substances is supposed in the light of a negative psychi-

atric history and no other concomitant medical treatments. An

important number of case reports documented deaths related to

the ingestion of mephedrone. Another problem is that these sub-

stances are not detected by standard blood and urine test so that

the diagnosis of intoxication is often delayed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1058

EV74

The experience of using synthetic

cannabinoids: A qualitative analysis of

online user self-reports

M. Newman

1 ,

, G. Denton

1

, T. Walker

1

, J. Grewal

2

1

University of Warwick, Warwick Medical School, Coventry, United

Kingdom

2

Caludon centre, Addiction Psychiatry, Coventry, United Kingdom

Corresponding author.

Introduction

The number of novel psychoactive substances (NPS)

available is increasing. Synthetic cannabinoids (SC) are one of many

NPS sold. SC aim to emulate the effects of natural cannabis by acting

on cannabinoid receptors. Despite much research into pharmacol-

ogy, there is limited data on the user experience of SC.

Aim

It is useful for psychiatrists, to understand what experiences

people have whilst on illicit substances. The aim of this qualitative

study is to gain an initial understanding of what characterizes the

experiences of those who use SC.

Method

Fourty anonymously written online reports were col-

lected from the “Erowid experience vaults” and analysed using the

Empirical Phenomenological Psychological Method.

Results

The analysis yielded 488meaning units (MU). Thesewere

grouped into 36 categories revealing 5 broad themes: (1) physical

affects; (2) sensory distortions and distortions of perception; (3)

emotional and psychological effects; (4) re-dosing, addiction and

comedown effects; (5) similarities to other substances.

Conclusion

Synthetic cannabinoids have a mixed effect on users

with a myriad of experiences reported. Some experienced positive

results from their usage such as euphoria and relaxation, however

these were counter balanced by those who experienced some seri-

ous negative emotional and physical side effects such as anxiety,

paranoia, palpitations and convulsions. SC appear to often emulate

that of their natural counterpart, yet there is an unpredictability